

| <b>CURRICULUM VITAE</b>       |                                             |
|-------------------------------|---------------------------------------------|
| <b>INFORMAZIONI PERSONALI</b> |                                             |
| Cognome e Nome                | ZANUSO VALENTINA                            |
| Qualifica                     | Medico Chirurgo<br>Specialista in Oncologia |

|                           |                                              |
|---------------------------|----------------------------------------------|
| Amministrazione           | ASST Melegnano Martesana                     |
| Incarico attuale          | Dirigente medico                             |
| Numero telefonico Ufficio | 02 98052383                                  |
| E-mail istituzionale      | valentina.zanuso@asst-melegnano-martesana.it |

| <b>Titoli di Studio e Professionali ed Esperienze lavorative</b> |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Titolo di Studio                                                 | Laurea in Medicina e Chirurgia conseguita presso l'Università degli Studi di Pavia in data 25/07/2018                                                                                                                                                                                                                                                                                                                  |
| Altri titoli di Studio e Professionali                           | Specializzazione in Oncologia conseguita presso Humanitas University in data 11/11/2024                                                                                                                                                                                                                                                                                                                                |
| Esperienze Professionali (Incarichi ricoperti)                   | <p>Dal 01/08/2024 Dirigente Medico presso Struttura Complessa Oncologia del Presidio Ospedaliero di Vizzolo Predabissi (Melegnano, Milano)</p> <p>Dal 01/05/2023 al 31/10/2023 Internato di Ricerca c/o School of Cancer Sciences, University of Glasgow</p> <p>Dal 04/11/2019 al 11/11/2024 Medico Specializzando presso Unità Operativa di Oncologia Medica, IRCCS Humanitas Research Hospital, Rozzano (Milano)</p> |

| Capacità linguistiche | Lingua   | Livello Parlato | Livello Scritto |
|-----------------------|----------|-----------------|-----------------|
|                       | Inglese  | Fluente         | Fluente         |
|                       | Tedesco  | Scolastico      | Scolastico      |
|                       | Francese | Scolastico      | Scolastico      |

| Capacità nell'uso delle tecnologie | Capacità             |        |
|------------------------------------|----------------------|--------|
|                                    | Applicativi          |        |
|                                    | Office               | Ottima |
|                                    | Database             | Ottima |
|                                    | Navigazione Internet | Ottima |
|                                    | Posta Elettronica    | Ottima |

|                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Altro</b> (partecipazione a corsi, convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)<br><u>Indica le date di inizio e fine e l'Attività</u> | <p>Autore e/o Coautore di diversi lavori scientifici prevalentemente in campo oncologico</p> <ul style="list-style-type: none"> <li>Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofe L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquez MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djabballah SA, <b>Zanuso V</b>, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large,</li> </ul> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

real-life, worldwide population. J Natl Cancer Inst. 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155. PMID: 40608977.

- Gairing SJ, Mildenerberger P, Gile J, Artusa F, Scheiner B, Leyh C, Lieb S, Sinner F, Jörg V, Fruendt T, Himmelsbach V, Abedin N, Sahin C, Böttcher K, Schuhbaur J, Labuhn S, Korolewicz J, Fulgenzi CAM, D'Alessio A, **Zanuso V**, Huckle F, Röhlen N, Ben Khaled N, Ramadori E, Müller L, Weinmann A, Kloeckner R, Galle PR, Tran NH, Venkatesh SK, Teufel A, Ebert M, De Toni EN, Waldschmidt DT, Marquardt JU, Bettinger D, Peck-Radosavljevic M, Geier A, Reiter FP, Rimassa L, Pinato DJ, Roderburg C, Ettrich T, Bitzer M, Scheble V, Ehmer U, Berres ML, Finkelmeier F, Gonzalez-Carmona MA, von Felden J, Schulze K, Venerito M, van Bömmel F, Jochheim LS, Pinter M, Mohr R, Ilyas SI, Schmidtman I, Foerster F. Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab. JHEP Rep. 2024 Dec 5;7(3):101295. doi: 10.1016/j.jhepr.2024.101295. PMID: 40059970; PMCID: PMC11889551.
- Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, **Zanuso V**, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population. Oncologist. 2025 Mar 10;30(3):oyae256. doi: 10.1093/oncolo/oyae256. PMID: 39427227; PMCID: PMC11954499.
- **Zanuso V**, Tesini G, Valenzi E, Rimassa L. New systemic treatment options for advanced cholangiocarcinoma. J Liver Cancer. 2024 Sep;24(2):155-170. doi: 10.17998/jlc.2024.08.07. Epub 2024 Aug 8. PMID: 39113642; PMCID: PMC11449581.
- Viganò L, **Zanuso V**, Fiz F, Cerri L, Laino ME, Ammirabile A, Ragaini EM, Viganò S, Terracciano LM, Francone M, Ieva F, Di Tommaso L, Rimassa L. CT-based radiogenomics of intrahepatic cholangiocarcinoma. Dig Liver Dis. 2025 Jan;57(1):118-124. doi: 10.1016/j.dld.2024.06.033. Epub 2024 Jul 12. PMID: 39003163.
- Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, **Zanuso V**, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. Eur J Cancer. 2024 Sep;208:114199. doi: 10.1016/j.ejca.2024.114199. Epub 2024 Jun 30. PMID: 39002348.
- **Zanuso V**, Pirozzi A, Tesini G, Rimassa L. Review of immune therapy in HCC: Where are we now and what is the future? Clin Liver Dis (Hoboken). 2024 Jun 14;23(1):e0149. doi: 10.1097/CLD.0000000000000149. PMID: 38881724; PMCID: PMC11177817.

- **Zanuso V**, Nash T, Casolino R, Armstrong G, Pallise O, Milne J, Braconi C. Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. *BMC Cancer*. 2024 May 16;24(1):597. doi: 10.1186/s12885-024-12279-6. PMID: 38755562; PMCID: PMC11097428.
- Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, **Zanuso V**, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. *Target Oncol*. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. PMID: 38691295.
- **Zanuso V**, Pirozzi A, Balsano R, Pressiani T, Rimassa L. Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma. *J Hepatocell Carcinoma*. 2023 Oct 2;10:1689-1708. doi: 10.2147/JHC.S347932. PMID: 37808223; PMCID: PMC10557510.
- **Zanuso V**, Rimassa L, Braconi C. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. *Hepatology*. 2025 Apr 1;81(4):1365-1386. doi: 10.1097/HEP.0000000000000572. Epub 2023 Sep 11. PMID: 37695554.
- Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Soldà C, Cito P, Nasti G, Lavacchi D, **Zanuso V**, Rizzato MD, Zaniboni A, Ottaiano A, Persano M, Cornara N, Scartozzi M, Cascinu S, Casadei-Gardini A. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. *Ther Adv Med Oncol*. 2023 Jul 12;15:17588359231171574. doi: 10.1177/17588359231171574. PMID: 37457302; PMCID: PMC10345913.
- Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, **Zanuso V**, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. *Liver Int*. 2023 Aug;43(8):1803-1812. doi: 10.1111/liv.15641. PMID: 37452505.
- Balsano R, **Zanuso V**, Pirozzi A, Rimassa L, Bozzarelli S. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. *Curr Oncol*. 2023 Mar 30;30(4):3871-3885. doi: 10.3390/curroncol30040293. PMID: 37185406; PMCID: PMC10136659.
- Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, **Zanuso V**, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. *Hepatol Int*. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1. PMID: 37005953; PMCID: PMC10386929.
- Cammarota A, **Zanuso V**, Manfredi GF, Murphy R, Pinato DJ, Rimassa

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>L. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing? Ther Adv Med Oncol. 2023 Jan 10;15:17588359221148029. doi: 10.1177/17588359221148029. PMID: 36643654; PMCID: PMC9837292.</p> <ul style="list-style-type: none"><li>• Personeni N, Pressiani T, <b>Zanuso V</b>, Casadei-Gardini A, D'Alessio A, Valgiusti M, Dadduzio V, Bergamo F, Soldà C, Rizzato MD, Giordano L, Santoro A, Rimassa L. Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment. J Pers Med. 2022 Oct 17;12(10):1726. doi: 10.3390/jpm12101726. PMID: 36294865; PMCID: PMC9604940.</li><li>• Cammarota A, <b>Zanuso V</b>, Pressiani T, Personeni N, Rimassa L. Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. J Hepatocell Carcinoma. 2022 Sep 14;9:1011-1027. doi: 10.2147/JHC.S268293. PMID: 36128575; PMCID: PMC9482774.</li><li>• Cammarota A, <b>Zanuso V</b>, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. Expert Opin Investig Drugs. 2022 Apr;31(4):425-435. doi: 10.1080/13543784.2022.2042253. Epub 2022 Feb 22. PMID: 35152830.</li><li>• Cammarota A, <b>Zanuso V</b>, D'Alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opin Investig Drugs. 2022 Apr;31(4):401-413. doi: 10.1080/13543784.2022.2032641. Epub 2022 Feb 10. PMID: 35072565.</li><li>• D'Alessio A, Cammarota A, <b>Zanuso V</b>, Pressiani T, Personeni N, Rimassa L. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Rev Anticancer Ther. 2021 Sep;21(9):927-939. doi: 10.1080/14737140.2021.1948329. Epub 2021 Aug 17. PMID: 34167423.</li><li>• Prete MG, Cammarota A, D'Alessio A, <b>Zanuso V</b>, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Explor Target Antitumor Ther. 2021;2(5):416-433. doi: 10.37349/etat.2021.00054. Epub 2021 Oct 31. PMID: 36045701; PMCID: PMC9400707.</li><li>• <b>Zanuso V</b>, Fregoni V, Gervaso L. Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study. Future Sci OA. 2020 Aug 10;6(9):FSO617. doi: 10.2144/fsoa-2020-0076. PMID: 33235809; PMCID: PMC7668125.</li></ul> <p>Partecipazione a congressi e corsi di aggiornamento in campo oncologico</p> <ul style="list-style-type: none"><li>• 18/02/2025 Partecipazione all'evento "IEO NET TUMOR BOARD: Strategie diagnostico terapeutiche multidisciplinari"</li><li>• 19-21/12/2024 Partecipazione al congresso "Grandangolo 2024. Un anno di Oncologia"</li><li>• 14-15/12/2023 Partecipazione al congresso "Grandangolo 2023. Un anno di Oncologia"</li><li>• 15-16/09/2023 Partecipazione al corso di formazione "ESMO Advanced Course on Cholangiocarcinoma: Where are we going?"</li><li>• 16/02/2023 Partecipazione al meeting "Lo studio HIMALAYA nel trattamento dell'HCC avanzato"</li><li>• 15-17/06/2022 Partecipazione al corso di formazione "Il colangiocarcinoma: dalla teoria alla pratica"</li></ul> |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*Quanto dichiarato è conforme alle disposizioni degli artt. 46 e 47 del DPR 445/00; il sottoscritto/a è a conoscenza che, ai sensi dell'art. 76 del D.P.R. 445/00, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del Codice penale e delle leggi speciali.*

*Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 GDPR 679/16 ed ai sensi del D.lgs. 101/2018*

Data 24/10/2025

FIRMATO